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Abstract
Full length TrkC (TrkC-FL) is a receptor tyrosine kinase whose mRNA can be spliced to a
truncated TrkC.T1 isoform lacking the kinase domain. Neurotrophin-3 (NT-3) activates
TrkC-FL to maintain motor neuron health and function and TrkC.T1 to produce neurotoxic
TNF-α; hence resulting in opposing pathways. In mouse and human ALS spinal cord, the
reduction of miR-128 that destabilizes TrkC.T1 mRNA results in up-regulated TrkC.T1 and
TNF-α in astrocytes. We exploited conformational differences to develop an agonistic mAb
2B7 that selectively activates TrkC-FL, to circumvent TrkC.T1 activation. In mouse ALS,
2B7 activates spinal cord TrkC-FL signals, improves spinal cord motor neuron phenotype
and function, and significantly prolongs life-span. Our results elucidate biological para-
doxes of receptor isoforms and their role in disease progression, validate the concept of
selectively targeting conformational epitopes in naturally occurring isoforms, and may
guide the development of pro-neuroprotective (TrkC-FL) and anti-neurotoxic (TrkC.T1)
therapeutic strategies.
Introduction
Neurotrophins play a key role in the life, maintenance, phenotype, and function of adult neu-
rons [1]. Specifically for motor neurons, Brain-derived neurotrophic factor (BDNF) and Neu-
rotrophin-3 (NT-3) regulate survival, excitability, axon conduction velocity, and morphology
[2] through activation of their respective receptor tyrosine kinases (RTKs) TrkB and TrkC
[2,3].
Motor neurons degenerate in Amyotrophic lateral sclerosis (ALS), spinal muscular atrophy
(SMA), and spinal cord injury (SCI) [4], and neurotrophic strategies that delay or prevent
motor neuron death and rescuemotor neuron functionmay be beneficial. Experimental ALS
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therapy required very high neurotrophin protein concentrations by intrathecal injections or
expression by viral vectors [5] or a combination of at least two growth factors [6–8].
While the rationale of using BDNF and NT-3 as drugs for ALS seems strong, they have
failed clinically [3]. There are several reasons postulated for the failure. One problem is that
neurotrophins have a short half-life in vivo and may not reach the target tissue. A second prob-
lem relates to the vast expanse of tissue that needs to be reached, from peripheral nerve termi-
nals to spinal cord, because TrkB and TrkC targets are distributed throughout the motor
neuron. Activation of receptors at the neuromuscular junction in the periphery versus recep-
tors at the neuronal cell body in the spinal cord result in transduction of different signals (neur-
itogenic versus neurotrophic pathways respectively) [9]. A neuroprotective therapy would
require activation of both receptors pools.
A third problem is that NT-3 not only binds to pro-survival receptor full length TrkC
(TrkC-FL), but also binds to receptors that have pro-inflammatory or neurodegenerative func-
tions: p75NTR and truncated isoforms of TrkC (TrkC.T1). The unintended p75NTR target is
expressed in most neurons, glia, and many other cell types. The p75NTR functions to execute
the axonal pruning and cell death required during embryonic development [10], and it is up-
regulated in ALS [11]. When neurotrophins are used as drugs it is essential to circumvent acti-
vation of p75NTR, and this has been achieved in vivo using neurotrophin mutants or p75-block-
ing strategies [12–14]. The unintended TrkC.T1 truncated isoform target is an mRNA splice
variant that lacks the kinase intracellular domain, but retains the ectodomain and transmem-
brane primary sequence identical to TrkC-FL [12]. While TrkC-FL has trophic activity, multi-
ple lines of evidence (biochemical, cell biological, genetic, and pharmacological) indicate that
TrkC.T1 activates Rac1 and can be deleterious to neurons [15,16]. However, discriminating
betweenTrkC-FL and TrkC.T1 activity is difficult becauseNT-3 binds to both isoforms with
equal affinities [17].
To circumvent the problems associated with the use of NT-3 as a therapeutic (binding
p75NTR and TrkC.T1, short half-life, not reaching all receptor pools), we used antibody-based
ligands [3,17–19] to develop a selective agonist that can discriminate betweenTrkC-FL and
TrkC.T1 isoforms even though these receptors have identical ectodomain primary sequences.
Selectivitywas achieved by targeting disulfide-stabilizedectodomain secondary structures in
TrkC-FL, structures which are absent in TrkC.T1 due to the influence of an intracellular neoe-
pitope of TrkC.T1.
We also demonstrate that TrkC.T1 is up-regulated in mouse and human ALS, due to
decreasedmiR-128, a miR that destabilizes TrkC.T1 mRNA. TrkC.T1 protein and mRNA are
present in activated spinal cord astrocytes, and we show ex vivo that in an NT-3–dependent
manner TrkC.T1 mediates up-regulation of TNF-α. Therefore, using the TrkC-FL selective
agonist, and validate ligand-dependent activation of this target for therapy in a mouse model
ALS.
Together, these data elucidate biological paradoxes of growth factor receptors and their iso-
forms in disease progression, validate the concept of selective targeting of conformational epi-
topes present in naturally occurring receptor isoforms of identical primary sequence, and
validate selective activation of TrkC-FL as a therapeutic target in model of ALS.
Results
MAb 2B7 binds selectively to full-length TrkC
MAb 2B7 and its Fab bind to an ectodomain epitope near the transmembrane domain [20].
FACScan studies demonstrated that mAb 2B7 binds to cells expressing surface TrkC-FL but
does not bind (or binds very poorly) to cell surface TrkC.T1 (Fig 1A). Binding to the cell
Selective TrkC-FL Agonist as Therapy for Motor Neuron Dystrophy
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Fig 1. 2B7 mAb binds only to full length TrkC. (A) HEK293-TrkC-FL or HEK293-TrkC.T1 cells were studied
by FACScan. HEK293 wild type cells are negative control. MAb 2B7 (red histograms) binds to cell surface
TrkC-FL protein, at mean channel fluorescence ~300. Several isotype-matched controls are shown for
background, all at mean channel fluorescence ~10. No significant binding to the cell surface was detected
using mAb 2B7 on NIH-TrkC.T1 cells, mean channel fluorescence ~15. (B) Non-reducing western blots of
HEK293-TrkC-FL or HEK293-TrkC.T1 cells. MAb 2B7 only recognizes lysates form TrkC-FL cells. A control
antibody 750 (against an intracellular neo-epitope that appears due to mRNA splicing) only recognizes TrkC.
T1 and demonstrates that the cells express TrkC.T1 protein. (C) Fluorescent microscopy of 293-TrkC-FL or
293-TrkC.T1 cells immunostained with primary mAb 2B7, or antibody 750, or with non-binding mouse IgG
control (red). DAPI counterstain for nuclei. Pictures were taken using a Leica confocal microscope with 63x
magnification. MAb 2B7 only recognizes full length TrkC, whereas antibody 750 only recognizes TrkC.T1. (D)
Lysates were prepared from HEK293-TrkC-FL or HEK293-TrkC.T1 cells and split as equal samples. For
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surface was measured on live HEK293 cells stably transfected to express equal numbers of
either TrkC-FL or TrkC.T1 (cDNAs were expressed so there is no possible mRNA truncation).
2B7 binding to TrkC-FL and not to TrkC.T1 was evaluated after transfection of human and rat
cDNAs, with similar results.
These FACScan studies are quantitative, as they use a homogeneous population expressing
a single receptor isoform, they yield single bell-shaped histograms that can detect ~1,000 recep-
tors/cell, with data from 5,000 to 10,000 cells acquired per experiment (n>10 independent
experiments), and in each independent experiment the TrkC-FL signal shifted>25-fold above
background and the TrkC.T1 signal shifted<2-fold above background).
FACScan studies using rat rMC-1 cells endogenously expressing TrkC.T1 mRNA and pro-
tein showed undetectable binding by mAb 2B7, and previous studies demonstrated 2B7 bind-
ing to TrkC-FL endogenously expressed in rodent primary neuronal cultures [3]. The 2B7
epitope is at the juxtamembrane in the ectodomain, and both TrkC-FL and TrkC.T1 have the
primary sequence of the epitope (Fig 1B). Previously, we showed that in western blots mAb
2B7 bound to TrkC-FL under non-reducing conditions but not under fully reducing conditions
[21,22]. Here, we show in western blot studies using non-reduced samples that mAb 2B7 binds
to 293-TrkC-FL whole cell lysates but it does not bind to 293-TrkC.T1 whole cell lysates. In
contrast, a control 750 antibody against the TrkC.T1 intracellular neo-epitope binds to
293-TrkC.T1 whole cell lysates but not 293-TrkC-FL whole cell lysates (Fig 1B). In immuno-
fluorescence studies mAb 2B7 binds to 293-TrkC-FL and antibody 750 binds to 293-TrkC.T1
(Fig 1C) without significant cross-reactivity. These studies were replicated in cells expressing
TrkC-FL or TrkC.T1 after transfection with human, mouse or rat cDNAs, with identical results
(data not shown).
Together, these data indicate that mAb 2B7 binds specifically to the ectodomain of cell sur-
face TrkC-FL frommouse, rat, and human species, but it does not bind to any TrkC.T1 species
whether it is expressed after transfection or expressed endogenously.
Receptor conformation determines ligand selectivity
MAb 2B7 binding is sensitive to full reduction of TrkC-FL (75 mMDTT, 5 min 100°C), sug-
gesting that a disulfide bond-stabilized secondary structure is required for proper display of the
epitope [23]. Both TrkC-FL and TrkC.T1 proteins have disulfide bonds. TrkC-FL migrates in
SDS-PAGE as Mr ~15 kDa smaller than when fully reduced (Mr ~120 kDa and ~135 kDa
bands respectively), and TrkC.T1 migrates in SDS-PAGE as Mr ~25 kDa smaller than when
fully reduced (Mr ~100 kDa and ~125 kDa bands respectively), as detected using antibody
C44H5 that binds to all TrkC isoforms (Fig 1D). TrkC.T1 migrates faster due to the truncation,
and both TrkC-FL and TrkC.T1 migrate more slowly in their reduced state due to the “relaxed”
state of the proteins. The minor bands detected by C44H5 likely correspond to differentially
glycosylated receptors [23].
Both TrkC-FL and TrkC.T1 were subjected to mild to intermediate reducing conditions (0,
0.1, 1.0 and 10 mMDTT ± 1 min 90°C). These conditions preferentially reduce disulfide bonds
exposed on the protein surface. MAb 2B7 detects non-reduced TrkC-FL as a single band of Mr
~120 kDa (Fig 1E lane 1), and mild reduction generates a “relaxed” protein Mr ~125 kDa, and
immunoblotting with mAb C44H5 (total TrkC). Samples were resolved in SDS-PAGE either non-reduced or
fully reduced (50 mM 2-ME, with 5 min boiling). (E) Immunoblotting with mAb 2B7 (TrkC-FL specific). Samples
were exposed to increasing amounts of reducing agent for 15’ at room temperature, and a replicate sample
containing 10 mM 2-ME (10*) was also heated to 90˚C for 1 min. Equal loading in all lanes was verified. Data
representative of n = 3 independent experiments with equal results. The major specific bands are indicated by
arrows and letters. The Mr of the bands on SDS-PAGE changes upon mild reduction.
doi:10.1371/journal.pone.0162307.g001
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intermediate reduction yields a Mr ~135 kDa band (Fig 1E, lanes 2–5). These mild/intermedi-
ate reducing conditions do not affect the mAb 2B7 epitope in TrkC-FL, and therefore could be
used to study “gain of epitope” in TrkC.T1. MAb 2B7 does not detect non-reduced TrkC.T1
(Fig 1E lane 6). Mild and intermediate reduction affords progressively improved detection of
TrkC.T1 by mAb 2B7 (Fig 1E, lanes 7–10).
Together, the data show that 2B7 selectively binds to TrkC-FL, at an epitope sensitive to
disulfide bond arrangements which differ betweenTrkC-FL and TrkC.T1, and which can be
resolved by mild reduction of exposedCys-Cys bonds at the protein surface.
A differential folding observed for TrkC-FL and TrkC.T1 (as defined by mAb 2B7 binding)
suggest that either the loss of the intracellular TrkC-FL kinase domain or the gain of the 84
amino acid neo-epitope in the TrkC.T1 cytoplasmic tail affects how each protein is processed.
These possibilities were evaluated (Fig 2) by expression of a TrkC.T1 cDNA construct where
the 84 amino acid neo-epitope was deleted (TrkC.T1Δinsert). Expression of TrkC.T1 Δinsert
resulted in proteins recognizedby mAb 2B7 at the cell surface in FACScan assays (Fig 2A) and
in non-reducing western blots (Fig 2B).
Together, these data demonstrate that a naturally occurring truncated isoform TrkC.T1
containing an intracellular neo-epitope has a new and different folding/conformation than
TrkC-FL, not recognizedby mAb 2B7. Deletion of the intracellular neo-epitope generates a
structure that is recognizedby mAb 2B7, like the TrkC-FL folding/conformation.
The three species we studied (human, rat and mouse) preserve the mRNA splicing that gen-
erates TrkC.T1, the neo-epitope of the intracellular domain of TrkC.T1, and the specific con-
formation of the ectodomain of each isoform (as defined by mAb 2B7). These data suggest an
important function for TrkC.T1. The TrkC.T1 isoform transduces signals [23] linked to neuro-
degeneration [15], but its mechanism of action remained unclear. Given that NT-3 binds
equally to TrkC-FL and to TrkC.T1, while mAb 2B7 is a selective ligand of TrkC-FL, we carried
out functional studies to test the ligand-dependentmechanisms of action.
TrkC.T1 induces TNF-αmRNA and protein in a ligand-dependent
manner
A rat glial cell line (rMC-1) endogenously expressing TrkC.T1 was studied after treatment with
TrkC agonists. NT-3 significantly increased the secreted form of TNF-α (Fig 3A, ELISA of
conditionedmedia, p<0.004 versus untreated cells), and increased the cell-bound form of
TNF-α (Fig 3B, cell immunofluorescence). NT-3 up-regulated TNF-α to levels similar to posi-
tive control LPS (a ligand of Toll-like receptors), and to levels higher than positive proNGF, a
control p75NTR agonist known to increase TNF-α [23]. Several doses of mAb 2B7 did not
increase TNF-α in conditionedmedia (Fig 3A) or in the cellular biomass (Fig 3B). The failure
of mAb 2B7 to induce TNF-α via TrkC.T1 is consistent with mAb 2B7 not binding to TrkC.T1.
Note that a full range of concentrations were tested, but to simplify the graphics only the opti-
mal or biologically active concentrations of ligands (e.g. 100 nMmAb 2B7 verified to act as
agonist of TrkC-FL) are shown.
NT-3 induction of TNF-α is dependent on TrkC.T1 expression, as shown by lack of TNF-α
stimulation by NT-3 when TrkC.T1 expression is specifically silenced. TrkC.T1 mRNA was
silenced in rMC-1 cells by infectionwith lentivirus PLKO.1TrkC.T1 expressing a unique shRNA
sequence that destabilizes TrkC.T1 mRNA. Infection with PLKO.1TrkC.T1 reduced TrkC.T1
mRNA (Fig 3C) and protein (Fig 3D) without affecting TrkC-FL mRNA or protein, and con-
trol virus PLKO.1Scrambled had no effect on expression of either TrkC.T1 or TrkC-FL mRNA
and protein. Silencing TrkC.T1 mRNA and protein significantly prevented the NT-3–induc-
tion of TNF-αmRNA (Fig 3E) and protein (Fig 3F) (p<0.04 versus PLKO.1Scrambled). As
Selective TrkC-FL Agonist as Therapy for Motor Neuron Dystrophy
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Fig 2. Deletion of the intracellular neo-epitope of TrkC.T1 affords 2B7 mAb recognition of the ectodomain. (A) The
neo-epitope of TrkC.T1 (see Fig 1B) was deleted to generate TrkC.T1 Δinsert. TrkC-FL, TrkC.T1, and TrkC.T1 Δinsert were
each transfected in HEK293 cells. After drug selection stable transfectants or control cells were studied by FACScan binding
assays using mAb 2B7. (B) Lysates of the same cells were studied by western blotting with mAb 2B7 or with mAb C44H5
(total TrkC).
doi:10.1371/journal.pone.0162307.g002
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Fig 3. NT-3–dependent induction of TNF-α is TrkC.T1–mediated. (A) The glial rMC-1 cell line expressing endogenous
TrkC-FL and TrkC.T1, and p75NTR were treated for 6 hours (NGF 2 nM, proNGF 0.5 nM, 2B7 100 nM, NT-3 10 nM, LPS 1 μg/
ml). From conditioned media the levels of soluble TNF-α protein were quantified by ELISA. Data are standardized to
untreated control. Average ± SEM, n = 3 independent experiments each in triplicate. * p<0.05, ** p< 0.01 versus control. (B)
The levels of cell-associated TNF-α protein were studied by immunofluorescence. (C) The mRNA levels of TrkC-FL and
TrkC.T1 were quantified by PCR, after infection with lentivirus pLKO.Scr (scrambled control) or with pLKO.1 (expressing a
unique shRNA targeting TrkC.T1 mRNA specifically). Results are normalized to reference GAPDH mRNA. Data are
expressed as the mean + SEM; n = 3 independent experiments each in triplicate. The inset shows a western blot for TrkC-FL
or TrkC.T1, from detergent lysates prepared from the cultures. (D and E) The levels of TNF-αmRNA or protein were
quantified by PCR or by ELISA after infection with pLKO.Scr or pLKO.1. Data are standardized to untreated control.
Average ± SEM, n = 3 independent experiments each in triplicate. (F) The levels of TNF-αmRNA in were assessed by
quantitative PCR from spinal cord of ALS G93A versus wild type mice. Results were normalized to GAPDH. Data are
expressed as the mean + SEM n = 8 independent spinal cords per group. (A–F) t-test was applied for statistical analysis. *
p<0.05, ** p< 0.01 versus control. Brackets indicate differences between the indicated groups.
doi:10.1371/journal.pone.0162307.g003
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internal control, in PLKO.1TrkC.T1 silenced cells the induction of TNF-α by LPS was not
affected, and PLKO.1Scrambled infection did not prevent induction of TNF-α by NT-3 or LPS
treatment.
Together, the data indicate that TrkC.T1 regulates production of TNF-α in an agonist-
dependent manner, and this could be a confounding factor when using NT-3 for ALS therapy.
Therefore we studied the expression and the role of each TrkC isoform in ALS.
TrkC.T1 up-regulation in spinal cord astrocytes in a mouse ALS model
and human sporadic ALS is due to miR128 downregulation
In the spinal cord of symptomatic G93A ALS mice TrkC.T1 mRNA expression is significantly
elevated, compared to wild type mice (p< 0.04). In contrast, expression of full-lengthTrkC
(TrkC-FL) mRNA does not differ betweenALS mice and wild type mice (Fig 4A). Standardiza-
tion versus β-tubulin (a neuronal marker, to account for neuronal loss), or versus GAPDH (a
ubiquitous marker) yields comparable results.
TrkC-FL and TrkC.T1 have non-overlapping 3'UTRs, and they are differentially regulated
at the post-transcriptional level. The spliced TrkC.T1 mRNA is destabilized by micro-RNA
miR128 [24]. In healthy wild type spinal cord miR128 is expressed. Pre-symptomatic ALS
spinal cords (~100 days of age) have lower miR128, and symptomatic ALS spinal cords
(~140 days of age) have even lower miR128 levels (p<0.003). In contrast, miR-151-3p that
regulates full length TrkC-FL mRNA remains unchanged in wild type versus ALS mice (Fig
4B) and this miRNA serves as internal control. A miR128-promoted degradation would
explain why healthy spinal cords have low or undetectable TrkC.T1 mRNA and protein,
whereas reducedmiR128 levels would lead to increased TrkC.T1 mRNA in the mouse model
of ALS.
Similar results were obtained in spinal cords obtained post-mortem from human sporadic
ALS (SALS, n = 4) versus non-ALS control (n = 3). In SALS there is a significant 2.84 ± 0.35
fold-increase in TrkC.T1 mRNA and a small non-significant elevation of TrkC-FL mRNA
(standardized versus β-tubulin) (Fig 4C). Elevated TrkC.T1 mRNA in human SALS is associ-
ated with significantly reduced levels of miR128 (a known disruptor of TrkC.T1 mRNA) ver-
sus non-ALS control (Fig 4D) normalized to the reference RNU6 small nuclear RNA. In
human SALS there was also a reduction in miR-151-3p (a known disruptor of TrkC-FL) ver-
sus non-ALS control and this resulted in a small and non-significant elevation of TrkC-FL
mRNA.
The cells that express TrkC.T1 protein and mRNA in spinal cord were identified. Immuno-
histochemical studies using a specific TrkC.T1 antibody 750, showed expression in GFAP+
cells (astrocytes) of symptomatic ALS mice (Fig 4E), but not in Iba-1+ cells (microglia) or
NeuN+ cells (neurons) (data not shown). In control wild type healthy spinal cords TrkC.T1
protein is virtually undetectable (Fig 4E), consistent with the very low number of GFAP+ acti-
vated astrocytes. These data were confirmed by in situ mRNA hybridization combined with
immunohistochemical studies in spinal cord of symptomatic ALS mice (Fig 4F). The GFAP+
phenotype and the morphology of TrkC.T1 mRNA-expressing cells indicate that they are acti-
vated astrocytes.
Together, the data demonstrate that elevated TrkC.T1 mRNA and reducedmiR128 are
detected in the mutant SOD1 mouse model, and also in humans with ALS unrelated to SOD1
mutations (which represent the majority of clinical cases). In ALS, up-regulation of TrkC.T1
mRNA and protein occurs in astrocytes rather than neurons. The neurotoxic nature of elevated
TNF-α in ALS has been documented, and our data provide a novel degenerative mechanism
where NT-3 acting through TrkC.T1 can drive production of TNF-α and cause neurotoxicity.
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Fig 4. TrkC.T1 expression is up-regulated whereas miR-128 expression is down-regulated in the
spinal cord of ALS G93A mice and in human SALS. (A)The mRNA levels of TrkC-FL and TrkC.T1 were
assessed by quantitative PCR with SYBR Green (Quanta), normalized to GAPDH or β-tubulin III, for WT
mice or ALS mice. Data are expressed as the mean + SEM (n = 8 spinal cord samples each group(B) The
levels of miR-128 (regulator of TrkC.T1) and miR-151-3p (regulator of TrkC-FL) were measured by SYBR
Green qRT-PCR (Quanta) and results were normalized to the reference RNU6 (small nuclear RNA). Data
are expressed as the mean + SEM. (C) Combined fluorescent in situ mRNA hybridization (red, for TrkC.T1
mRNA) with immunofluorecence (green, GFAP marker). 40x magnification of 20 μm-thick sections of the
lumbar spinal cord of G93A ALS mice. The probe specific for TrkC.T1 encompasses exons 13b & 14b as well
as some of the 3’UTR. (D) Co-localization of TrkC.T1 protein (using anti-TrkC.T1 antibody 750) and GFAP in
12 μm thick sections from G93A ALS mice (top panels) or wild type mice (bottom panels). Pictures were
taken using a Leica confocal microscope with 63x magnification. (E) The mRNA levels of TrkC-FL and TrkC.
T1 were assessed by quantitative PCR with SYBR Green (Quanta), normalized to β-tubulin III, for human
Selective TrkC-FL Agonist as Therapy for Motor Neuron Dystrophy
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TrkC-FL activation by mAb 2B7 and Fabs is long-lived
Previous work using neuronal cell lines and primary neuronal cultures showed that mAb 2B7
and 2B7 Fabs activate endogenously expressed TrkC-FL [17]. Here we show a detailed study of
the kinetics of activation by these agonists. Biological (cell survival assays, Fig 5A) and bio-
chemical (signal transduction assays, Fig 5B) show comparable activation by control NT-3,
mAb 2B7, and 2B7 Fabs, which is sustained for up to 4 hr. In Fig 5B some of the exposures are
not linear, this was intentional to show the longer time kinetics of some ligands. Quantifica-
tions were done from properly exposed gels and show that mAb 2B7 or 2B7 Fabs sustain the p-
AKT signal significantly longer (p< 0.0002) than NT-3, with the signal persisting>24 hours
(quantification in Fig 5C, 5D and 5E). In cellular controls, the mAb 2B7 and its Fabs do not
activate signals in cells transfected to express a receptor family member TrkA or TrkB (data
not shown).
Sustained activity is a known characteristic of the Trk receptor family and it is required for
neuronal survival [25,26].
2B7 and 2B7 Fabs are stable in vivo
The poor specificity of NT-3 (binding to multiple receptors TrkC-FL, p75NTR, TrkC.T1), poor
pharmacokinetics (circulation half-life under 2 minutes), and the inability to reach the different
pools of receptors make NT-3 a poor therapeutic agent for ALS. On the other hand, mAb 2B7
has high TrkC-FL selectivity, does not bind to TrkC.T1 or p75NTR, and it does not induce
increased TNF-α. Moreover, mAbs are known to be relatively stable in circulation.
For a pharmacokinetic study, 2B7 or 2B7 Fabs were administered intraperitoneally, and
serumwas prepared from blood samples collected over time. The presence of 2B7 or 2B7 Fabs
in serumwas quantified by ELISA against the original peptide epitope, as described [27,28].
Extrapolation from binding curves indicate that the half-lives of circulating and bioavailable
2B7 Fab and 2B7 mAb that are able to bind to the target were respectively ~36 hours and ~80
hours.
2B7 is present in spinal cord neurons and activates pro-survival signals
in spinal cord in vivo
We studied whether 2B7 administered at the periphery can reach the motor neuron cell body
in the spinal cord, a key feature for neurotrophic activity [29]. Labeled 2B7 was administered
intraperitoneally to wild type mice, and after 48 hours spinal cords were studied for the pres-
ence of labeled 2B7. The 2B7 signal was found in the cell bodies of putative ventral motor neu-
rons of lumbar spinal cord (Fig 6A), and there was no label in any other cells within the spinal
cord.
Then, we asked whether activation of TrkC-FL signals is detected in spinal cord after 2B7
treatment. Wild type mice received single intraperitoneal injection of 2B7 Fab or control
(~30 μg/mouse), and ~18 hours later the mice were saline-perfused, spinal cord tissues were
collected, and activation of trophic signals were quantified by western blots (n = 3 mice per
group). From densitometric quantification, the data shows that 2B7 treatment activated a sig-
nificant ~35% increase in p-AKT and a significant ~50% increase in p-PLCγ compared to
control (n = 3) or SALS (n = 4). Data are expressed as the mean + SEM. (F) From the same human samples
the levels of miR-128 (regulator of TrkC.T1) and miR-151-3p (regulator of TrkC-FL) were measured by
SYBR Green qRT-PCR (Quanta) and results were normalized to the reference RNU6 (small nuclear RNA).
Data are expressed as the mean + SEM. (A–F) t-test was applied for statistical analysis. * p<0.05, ** p<
0.01 versus control.
doi:10.1371/journal.pone.0162307.g004
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control treatment (Fig 6B). Note that these studies were done in freely moving wild type
healthy mice, which have normal motor neuron activity. Therefore the significant increases
reported are above normal signals.
To complement this study in wild type mice, a study evaluated activation of signals in the
spinal cord of ALS mice at post-natal day 102 (symptomatic, n = 5 mice per group). Data
shows activated p-Akt and p-MAPK in 2B7–treated mice, when compared to control IgG–
treated mice (Fig 6C) at ~18 hours post-injection. From these 2B7–treated or control–treated
ALS spinal cords, cryosectionswere prepared for immunohistochemical studies with anti-p-
Akt and anti-p-MAPK. The representative fluorescent microscopy data shows that 2B7 acti-
vates (i) p-Akt in neuronal cell bodies in the gray matter (co-localizedwith the NeuN marker)
and in neuronal fibers of the white matter; and (ii) p-MAPK almost exclusively in neuronal cell
bodies, but not in neuronal fibers of the white matter. In contrast, control-treated ALS mice
studied in parallel had lower or absent neuronal Akt and MAPK activation (Fig 6D).
Taken together, these data demonstrate that 2B7 treatment activates trophic signals significantly
above normal homeostatic levels in healthy wild typemice and in spinal cord neurons of symptom-
atic ALSmice. This suggests that therapy may be initiated after the onset of symptoms. Moreover,
2B7 treatment benefits from the key features of a relatively simple systemic administration.
Criteria for therapeutic dose
A dose and frequency for a therapeutic study in ALS mice was estimated from the pharmacoki-
netic study. A relatively low dose and frequency of drug were chosen from the pharmacokinetic
data. The rationale was based on the following reasons. First, the schedule has to be acceptable
for pharmacological treatment of chronic diseases such as ALS. Second, biochemical studies in
cultured cells confirmed that TrkC activation by the agonists was long-lived. Third, biochemi-
cal studies in vivo showed that within 18 hours of injection there was activated TrkC in the spi-
nal cord, and imaging studies showed that at 48 hours after injection the reagents were still
present in spinal cord neuronal cell bodies.Fourth, a receptor agonist should not require satu-
ration of all the receptor sites to activate signals, and a low level of agonist in the circulation
could activate TrkC without causing receptor desensitization or down-regulation (which
would be counterproductive). Fifth, pharmacokinetic experiments showed reasonable stability
in circulation after intraperitoneal injection.
2B7 Fabs extend life span, improve motor neuron performance, body
weight, and motor neuron phenotype in a mouse model of ALS.
A 0.5 mg/kg dose of 2B7 Fab or control non-binding IgG at a frequency of three times a week
was injected intraperitoneally in transgenic SOD1 G93Amutant mice.
Fig 5. 2B7 mAb and 2B7 Fab activate pro-survival activity and signaling pathways with sustained
kinetics. (A) 2B7 and 2B7 Fabs protects NIH-TrkC cells from apoptotic death triggered by culture in serum-
free conditions for 48 hours. NT-3 (2 nM) is the positive control, and was standardized as 100% since it is the
optimal concentration. In cells that do not express TrkC, none of the ligands afford survival, indicating a
TrkC-dependent signal (data not shown). Assay shown is representative of >5 independent experiments.
Each assay n = 4 ± SEM.(B) 293-TrkC cells were cultured with 2B7 mAb (50 nM), 2B7 Fab (100 nM), NT-3 (4
nM) or control mIgG (100 nM) for the indicated times. Detergent lysates were analyzed by Western blotting
for p-TrkC, p-MAPK, or p-Akt; standardized to actin. For these kinetic studies the molar concentrations of
ligands result in comparable activation. Some of the exposures are not linear, this was intentional to show the
longer time kinetics of some ligands. Quantifications were done from properly exposed gels. (C) p-TrkC
densitomeric quantification + SEM of 3 independent experiments. (D) p-MAPK densitomeric quantification
+ SEM of 3 independent experiments. (E) p-AKT densitomeric quantification + SEM of 3 independent
experiments. For visual clarity, the statistical differences are discussed in the text.
doi:10.1371/journal.pone.0162307.g005
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For the therapeutic study, we elected to use 2B7 Fabs (lacking the Fc domain) to eliminate
the potential for immune activation that could lead to misinterpretation. For example, we pre-
viously reported [15] that mAb 2B7 IgG could cause cell death in vivo but without detectable
binding to TrkC.T1. In retrospect neuronal death was likely caused by Fc receptor-binding,
activation of the complement cascade, and/or recruitment of macrophages.
In a realistic therapeutic paradigm treatment was initiated at postnatal day ~100 (after dis-
ease onset, when hind leg reflexes were compromised). Treatment was continued until postna-
tal day ~168. At postnatal day 160 the control group had 50% survivingmice whereas the 2B7
Fab group had 80% survivingmice. At postnatal day 168 (when treatment was discontinued)
the control group had 35% survivingmice whereas the 2B7 Fab group had 60% survivingmice.
At postnatal day 175 the control group had 0% survivingmice whereas the 2B7 Fab group had
60% survivingmice (Fig 7A). We note that the survivingmice in the 2B7 Fab group died pre-
cipitously between days 177 and 180 (9 days after discontinuation of treatment), and this is
coherent with drug elimination pharmacokinetics.
In addition to significantly increased survival (Fig 7A), the 2B7 Fab-treated group exhibited
significant (p< 0.01) improvement to motor performance in the rotarod test (Fig 7B), and
maintained body weight (Fig 7C). In addition, their spinal cord neurons had enhanced ChAT
and VAChT phenotype compared to control-treated ALS mice (Fig 7D).
In sum, 2B7 Fab therapy was effective in vivo in a mouse model of ALS, even when adminis-
tered after disease onset, demonstrating that selective TrkC-FL agonists can be significantly
and meaningfully effective in vivo, improving the key endpoints of life-span, motor function,
weight, and motor neuron phenotype. To our knowledge, no reported therapeutic treatment
has achieved such efficacy in these endpoints in this animal model.
Discussion
This work addresses the concept that functional ligands can selectively target the ectodomain
of receptors that have identical primary sequences and which are not discriminated by natural
ligands. Extension of this work to other receptors known to generate intracellular isoforms
would generalize the concept and help to validate important therapeutic targets.
Structural differences in TrkC-FL and TrkC.T1 ectodomain
To our knowledge, this is the first example of a mAb differentiating between naturally occur-
ring RTK ectodomains with identical primary structure.Moreover, the antibody acts as a
Fig 6. 2B7 reaches spinal cord neurons and induces trophic signals in wild type mice and in ALS mice. (A) 2B7 was labeled with Atto-
488 fluorochrome and 15 μg 2B7-ATTO were injected intraperitoneally into 6-week old C57BL/6J wild type mice. After 48 hrs, mice were
perfused, and sections of their spinal cord examined. Staining was observed in ventral motor neurons of lumbar spinal cord (smaller pictures
showing only one layer), and in confocal images (large picture on left). The label within subcellular organelles can be detected, indicative of
internalized fluorochrome within vesicles. Motor neurons at all levels of the spinal cord contained the label. (B) A single intraperitoneal
injection of 2B7 was done in wild type C57BL/6J mice (n = 3 per group), spinal cords were collected after 18 hrs, and detergent lysates of soft
tissues were prepared and studied by Western blots. Quantification of p-Akt or p-PLCγwas done by densitometric analysis versus actin to
standardize loading. The data shows activated p-Akt, and p-PLCγ in 2B7–treated mice, when compared to control IgG–treated mice. t-test *
p<0.05 versus control. (C) The quantitative data in (B) was validated using symptomatic ALS mice (post-natal day 102). ALS mice received a
single intraperitoneal injection of 2B7 or non-binding control IgG (n = 5 per group). After ~18 hrs spinal cords were collected for biochemical
and immunohistochemical studies. Detergent lysates of soft tissues were studied by Western blots using with anti-p-Akt, anti-p-MAPK, or
anti-actin to standardize loading. The data suggests activated p-Akt, and p-MAPK in 2B7–treated ALS mice, when compared to control IgG–
treated ALS mice. t-test * p<0.05 and ** p<0.01 versus control. (D) Immunohistochemical studies of ALS spinal cords. Cryosections of
2B7-treated or control-treated ALS mice (as in panel C) were immunostained with anti-p-Akt and anti-p-MAPK antibodies. Fluorescent
microscopy data shows that 2B7-treatment induced Akt activation in neuronal cell bodies in the gray matter (co-localized with the NeuN
marker) and in neuronal fibers of the white matter; and MAPK activation almost exclusively in neuronal cell bodies, but not in neuronal fibers
of the white matter. Akt and MAPK activation in neurons are not seen in control IgG-treated ALS samples.
doi:10.1371/journal.pone.0162307.g006
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functional agonist of TrkC-FL, while the natural ligand NT-3 does not discriminate between
isoforms. Our strategy is therefore distinct from other mAb-based ligands that target unique
structures generated by activating mutations in a receptor ectodomain [23].
The 2B7 epitope may be defined as a “receptor hot spot”, and it was surprising that it would
be expressed as a “cryptic epitope” in the TrkC.T1 isoform. The functional relevance of confor-
mation and “cryptic epitopes” has been documented for Trk-receptors. For example, it is possi-
ble to activate Trk with monvalent/monomeric ligands through putative conformational
mechanisms [26,30], rather than by directly inducing or stabilizing Trk-Trk dimers [23]. “Ago-
nistic hot spots” in Trk receptors can be unmasked by homotypic co-expression of p75NTR
Fig 7. 2B7 Fabs extend life-span and improve motor neuron performance and phenotype in a mouse
model of ALS. In transgenic SOD1 G93A mutant mice, non-binding control Ig or 2B7 Fabs were injected
intraperitoneally 3x/week at 0.5 mg/kg (~10 μg per dose). Treatments were initiated at day ~100 and continued
until day ~168. Experiments were done double-blinded, and 2B7 FAb was coded TX1. n = 12 mice per group. The
p values in survival and Rotarod Kaplan-Meier plots are derived from log-rank tests.(A) 2B7 Fab treatment
significantly extended life-span, p<0.037 versus control. The time at which therapy ended is indicated by red
arrows. (B) 2B7 Fab treatment significantly improved Rotarod performance. Shown are 1x per week
measurements starting at post-natal day ~100, p<0.01 versus control. The time-course of drug-treatment is
indicated by the red line. (C) 2B7 Fab treatment improved or maintained body weight. Shown are 1x per week
measurements starting at post-natal day ~100. The time-course of drug-treatment is indicated by the red line. (D)
The spinal cords of wild type control, and 2B7-treated or Ig-treated ALS mice were dissected at day 160 (n = 2 per
group). Cryosections were studied using fluorescent microscopy after immunostaining with anti-ChAT antibodies
(a marker of motor neuron cell body) or anti-VAchT antibodies (a marker of motor neuron cell body and fibers). The
ChAT and VAchT phenotype appears to be improved in 2B7-treated G93A ALS mice.
doi:10.1371/journal.pone.0162307.g007
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[31], and these hot spots can be regulated functionally by antibody-based ligands [32]. Overall,
these previous results support the notion of conformational regulation, throughmechanisms
that can be ligand-dependent.
The present work also demonstrates a third mechanism: that the gain of a neoepitope in the
intracellular domain may be instructive of extracellular domain protein folding. It will be
important to identify how the 2B7-recognized structure (TrkC-FL; TrkC.T1 Δinsert) and the
2B7-unrecognized structure (TrkC.T1) are formed, because it may be relevant to many recep-
tors that have splicing isoforms. Current work addresses this issue, under the hypothesis of dif-
ferential folding and S-S formation during Golgi-ER transport.
We show that ligand-dependent signals differ betweenTrkC-FL and TrkC.T1, and it is also
possible that functional differencesmay be independent of a conventional ligand. Synaptogen-
esis during development is regulated by physical interactions of TrkC.T1 with PTPsigma and
TrkC-FL appears to be less effective at this role [33]. Potentially the structural differences at the
ectodomains that we report here may contribute to specific physical interactions with
PTPsigma and we are currently exploring this hypothesis.
A strategy that simultaneously affords intracellular truncation together with conformational
changes to the ectodomainmay be an efficient use of a single gene to generate proteins with
different signal transduction properties (e.g. lacking a tyrosine kinase domain) and which can
also differentially interact with non-conventional “ligands” or co-receptors through homotypic
interactions (e.g. p75NTR on the same cell membrane) or heterotypic interactions (e.g.
PTPsigma on other cells), or to act as a conventional “dominant negative” inhibitor.
Receptor isoforms and disease
We used TrkC-FL agonist mAb 2B7 to validate selective agonist-dependent activation of this
target as a potential therapeutic strategy for ALS. Moreover, we showed the mechanism of
action by which TrkC.T1 plays a neurotoxic role in ALS, and suggest that TrkC.T1 antagonists
or silencingmay be potential therapeutics. Our results raise caution about the therapeutic use
of growth factors that can activate receptor isoforms, and specifically show the significant bar-
riers to the use of neurotrophins as drugs.
p75NTR receptors as therapeutic barriers
We conclude that avoiding engagement of p75NTR and TrkC.T1 seems essential in any thera-
peutic strategy. Neurotrophins bind to p75NTR, which has multiple actions that include pro-
death and pro-inflammatory signals [13]. p75NTR has widespread expression in motor neurons
[34], sensory and sympathetic neurons [35–37], and non-neuronal subtypes such as Schwann
cells [38,39]. The p75NTR is re-expressed during/following injury to recapitulate its develop-
mental role in axonal pruning and cell death [32], and the cleaved extracellular domain of
p75NTR is a biomarker in ALS [40,41].
In sum, p75NTR expression in cells not meant to be targeted and up-regulation in disease
would compromise the use of wild type neurotrophins. Indeed, p75NTR antagonists have mod-
est efficacy at delaying symptoms in ALS models, and engineered neurotrophins that do not
bind to p75NTR are neuroprotective whereas wild type neurotrophins are not [13,14].
TrkC.T1 receptors as therapeutic barriers
Biochemical and cell biological data indicate that TrkC.T1 signals differ from TrkC-FL [42]
and can activate RAC1 in a ligand-dependentmanner [43]. Genetic and pharmacological data
indicate that truncated TrkC.T1 is deleterious to neurons but the mechanism of action was
unclear [15]. Here we extend those studies to show that TrkC.T1 causes a paracrine neurotoxic
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damage by directly up-regulating TNF-α, most likely through RAC1 activation, which is
reported to up-regulate TNF-α.
Given the known role of TNF-α in human ALS [10], our data showing the role of TrkC.T1
at increasing neurotoxic TNF-α, and the correlation of TrkC.T1 up-regulation associated with
down-regulation of miR-128 and disease progression in human sporadic ALS and in an ALS
animal model, we suggest that TrkC.T1 may be a potential target for ALS therapy. This could
be achieved by using TrkC.T1 antagonists, Rac1 inhibitors, by silencing TrkC.T1 expression
using our pLKO.1TrkC-T1 vectors, or by re-expressing miR-128 to promote degradation of
TrkC.T1 mRNA. Current work is addressing these possibilities.
Poor pharmacokinetics and delivery as therapeutic barriers
Neurotrophins have very short half-lives in circulation [11]. The poor pharmacokinetics and
poor specificity of NT-3, combined with the inability of NT-3 to reach the vast expanse of tar-
get receptors (from neuromuscular junctions to motor neuron cell bodies in spinal cord behind
the blood brain barrier)makes them unsuitable as systemic drugs, and poor therapeutic agents
for ALS. Experimental treatments using NT-3 protein or viral vectors expressing NT-3 (as well
as therapies using many other growth factors) have generally failed for long-term therapy of
ALS and failed primary endpoints in human clinical trials [44,45].
Although NT-3 delivered to spinal cord could spare neurons in spinal cord, it did not
improve function or survival [14]. Likewise, adenoviruses expressing high levels of NT-3
injected in muscle protected the innervation of that specificmuscle but did not protect cen-
trally [6]. Another growth factor, IGF-1, also failed in ALS when injected subcutaneously [17]
or when expressed in muscle [17], but had some efficacy after intraspinal delivery using viral
vectors [46].
These results are consistent with the fact that signals at the neuromuscular junction differ
from signals at the cell body [47] and emphasize the importance of biodistribution and phar-
macokinetics to regulate the “location and tempo” of receptor activation required for neuronal
survival [48]. Direct and repeated injection of therapeutics in each muscle or in spinal cord is
problematic because of the large expanse that would need to be injected. A suitable therapy
would have to reach all target tissues at anatomically distant places, from a single delivery
route. MAbs as therapeutics are spared most or all of these problems.
TrkC-FL as a therapeutic target
MAbs are known to be relatively stable in circulation and mAb 2B7 and Fabs have a relatively
long circulating half-life, are bioavailable and can be detected in motor neurons of the PNS and
the CNS after a single systemic delivery. Additionally, 2B7 and Fabs are selective agonists for
the target TrkC-FL. Hence, we used a challenging therapeutic paradigmwith treatment initi-
ated after first signs of motor decline were detected. This is a realistic model because patients
would present with existing symptoms.
The therapeutic doses and frequency of 2B7 Fabs utilized are acceptable for treatment of
chronic diseases such as ALS.We rationalized a dose and frequency suitable to achieve and
maintain low-levels of circulating agonist, which would be sufficient to maintain a constant
pro-survival signal without causing desensitization.
While antibodies have been shown to be high-quality therapeutics for cancer and immune
disorders, the use of an agonist of an RTK also requires caution because of the potential for
oncogenicity. Indeed, TrkC-FL has roles in tumor development, including breast cancer and
adenoid cystic carcinoma, which could be a safety concern. On the other hand, targeting
TrkC-FL therapeutically could potentially extend to neurodegenerative pathologies other than
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ALS where TrkC-FL and NT-3 are relevant, such as proprioceptive neurons, the repair of inner
ear neurons damaged by noise, amongst others. Hence, it will be crucial to carry out detailed
pharmacokinetic and pharmacodynamic studies to optimize intervention for chronic
neurodegeneration.
The results presented here may guide the development of pro-neuroprotective (TrkC-FL)
and anti-neurotoxic (TrkC.T1) therapeutic strategies in ALS and related diseases.
Materials and Methods
Cell lines
Established cell lines HEK293 or NIH-3T3 were transfected with plasmids encoding human or
rat full-lengthTrkC (293-TrkC-FL, NIH-TrkC-FL) or coding for human or rat TrkC.T1
(293-TrkC.T1, NIH-TrkC.T1), or coding for TrkC.T1 with the neo-epitope deleted (293-TrkC.
T1 Δinsert). Stably transfected cell lines that express high levels of TrkC-FL or TrkC.T1 receptors
were generated and subcloned under drug selection (depending on the vector, 0.5 mg/ml G418,
or 2 mg/ml puromycin, or 10 mg/ml blastocidin). The HEK293 cell line expressing the human
TrkC.T1 Δinsert construct was generated by transfection with a pcDNA6 blasticidin-resistant
plasmid containing a PCR-generated amplicon encompassing amino acids 1 to 528 of human
TrkC.T1. The rat glial cell line, rMC-1, has been previously characterized [49].
Antibodies and Proteins
The mAb 2B7 is an agonistic anti-TrkC IgG-C2 (D5) domain antibody. Production and purifi-
cation of mAB 2B7 and its Fabs were performed as previously reported [7,50]. The epitope is
conserved in mouse, rat and human TrkC and the mAb is known to bind to these species. mAb
2B7 does not bind to p75NTR, TrkA, TrkB, and many other cell surface receptors tested. MAb
2B7 binds to cells transfected to express TrkC, but not to untransfected parental cells [6].
The mouse polyclonal 750 antibody was developed in our laboratory against a peptide com-
prising a neo-epitope which is present only in TrkC.T1 due to mRNA splicing (residues 595–
611 sequence GIYVEDVNVYFSKGRHG). The anti-GFAP is a rabbit polyclonal fromMilli-
pore. NGF, proNGF and NT-3 were purchased (Alomone Labs and ProSpec-Tany). The rabbit
anti-VAChT antibody was a gift from Dr. Claudio Cuello (McGill University) and the rabbit
anti-ChAT antibody was purchased (ThermoFisher).
RNAi knockdown of TrkC.T1
A short hairpin RNA (shRNA) specifically targeting a unique 3’ sequence of the TrkC.T1
mRNA was designed using the DSIR algorithm (http://biodev.cea.fr/DSIR/DSIR.html). The
TrkC.T1-targeting shRNA sequence (GGACAATAGAGATCATC TAGT), or a scrambled con-
trol sequence (CCTAAGGTTAAGTCGCCCTCG), were cloned into a pLKO.1 lentiviral
shRNA-expression vector. pLKO.1scrambled and pLKO.1TrkC-T1 lentiviral vectors were packaged
in HEK-293T cells and active viral particles were purified. rMC-1 cells were then transduced
with lentiviral particles, and selectedwith 1 μg/ml puromycin. TrkC.T1-specific depletion was
determined by real-time quantitative PCR and by Western blotting.
Expression of TNF-α, and TrkC isoforms
ALSmice. For mRNA expression, total RNA, including short RNAs, were extracted from
whole spinal cords (WTmice or ALS pre-symptomatic or symptomatic mice) using the miR-
Neasy1 Mini Kit (QIAGEN). One μg of extracted RNA was reverse transcribedwith the
SuperScript III First-Strand Synthesis System for RT-PCR (Invitrogen). mRNA levels of TrkC
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isoforms and TNF-α were analyzed by real-time quantitative PCR using SYBR Green I
(Quanta) in an 7500 FAST real-time PCR thermocycler (Applied Biosystems) and thermal
cycling was performed as follows: 94° C for 30 sec, followed by 40 cycles at 94° C for 5 sec, 60°
C for 30 sec. Specific primers were designed for the two TrkC isoforms and TNF-α. GAPDH or
β-tubulin III were used as housekeeping genes (Table 1). Data are expressed as the mean rela-
tive quantification (RQ) ± SEM (n = 8 individual mice per group). WT samples were used as a
calibrator (RQ = 1).
HEK293 cells. For quantification of TrkC protein, detergent lysates of 293-TrkC or
293-TrkC.T1 or TrkC.T1 Δinsert cells were analyzed by Western blotting with MAb 2B7, or anti-
body 750 specific for TrkC.T1 or Ab C44H5 for all isoforms. For analyses of cell surface expres-
sion, 293-TrkC or 293-TrkC.T1 cells were fixed and immunostained with primarymAb 2B7,
or antibody 750, or with non-bindingmouse IgG control. DAPI was used to stain nuclei.
Immunofluorescent pictures were taken using a Leica confocal microscopewith 63x
magnification.
RMC-1 cells. Non infected rMC-1 or cells infected with lentiviral pLKO.1scrambled or
pLKO.1TrkC.T1 were treated with 2B7 100 nM or NT-3 10 nM or LPS 1 μg/ml for 6 h. Quantifi-
cation of TNF-αmRNA was performed by real-time quantitative PCR as describedpreviously
and primers used for rat TNF-α and rat GAPDH are reported (Table 1). Quantification of
Table 1. Sequences of the primers.
Genes Amplicants bp
Mouse TrkC-FL 173
Forward: 5’- -3’ TGATCCTCGTGGATGGACAG
Reverse: 5’- -3’CTTCACTAGTAGATTGGCTCC
Mouse TrkC.T1 517
Forward 5’- -3’ CCACTTCCTGAAGGAGCCCT
Reverse 5’- -3’ CCCACTCTGGACCTCAGGTT
Human TrkC.T1 Δinsert 527
Forward: 5’- -3’CCCCTCGAGCCACCATGGATGTCTCTCTTTGCCCA
Reverse: 5’- -3’CTTACCGGTCTACGTGTCCGGCTTGTGGCAGT
Mouse TNF-α 235
Forward 5’- -3’GAGTCCGGGCAGGTCTACTTT
Reverse 5’- -3’CAGGTCACTGTCCCAGCATCT
Mouse Beta-Tubulin III 160
Forward 5’- -3’ CTCAGGGGCCTTTGGACATC
Reverse 5’- -3’ CAGGCAGTCGCAGTTTTCAC
Mouse GAPDH 452
Forward 5’- -3’ ACCACAGTCCATGCCATCAC
Reverse 5’- -3’ TCCACCACCCTGTTGCTGTA
Rat TrkC.T1 101
Forward 5’- -3’ GTCCAGAGTGGGGATGTGTC
Reverse 5’- -3’ CCATGGTTAAGAGGCTTGGA
Rat TNF-α 159
Forward 5’- -3’ CTATGTGCTCCTCACCCACA
Reverse 5’- -3’ TGGAAGACTCCTCCCAGGTA
Rat GAPDH 181
Forward 5’- -3’ AGCCCAGAACATCATCCCTG
Reverse 5’- -3’ CACCACCTTCTTGATGTCATC
doi:10.1371/journal.pone.0162307.t001
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TNF-α in supernatant (conditionedmedia) was done using commercial rat TNF-α Standard
ELISA (PeproTech). Data are expressed as the mean + SEM relative to the untreated (3 inde-
pendent experiments, each in triplicate). Cell-associated levels of TNF-α were studied in the
same cultures of rMC-1 cells treated as above, by immunofluorescence. Cells were fixed and
immunostainedwith primary rabbit anti-mouse TNF-α (Millipore) followed by incubation
with secondary anti-rabbit Alexa488 (Invitrogen). Immunofluorescent pictures were taken
using a Leica confocal microscope with 63x magnification to reveal cell-associatedTNF-α pro-
tein (surface, intracellular, and vesicular).
MicroRNA expression
MicroRNA cDNA synthesis was performedwith the qScript microRNA cDNA synthesis kit
(Quanta) using 1 μg of total spinal cord RNA. Then, a real time SYBR Green qRT-pCR amplifi-
cation of miRNAs were performed using 200 nM of each Perfecta microRNA assay primers for
miR-128-1 (destabilizes TrkC.T1), miR-151-3p (destabilizes TrkC-FL) [51], or RNU6 (as refer-
ence) and universal primers (Quanta). qRT-PCR was performed using an 7500 FAST real-time
PCR thermocycler (Applied Biosystems) and thermal cycling was performed as follows: pre-
incubation/activation; 95° C for 2 min, followed by 40 cycles at 94° C for 5s, 60° C for 30s. The
WTmRNA sample was used as a calibrator (RQ = 1). Data are expressed as the mean + SEM
from 6 individual mouse spinal cords of ALS or WT.
Human spinal cord samples
Samples were collected post-mortem under a protocol from the Institutional ReviewEthic
Board (Brain Research Centre, UBC), with written informed consent from the donor or the
next of kin. The Institutional ReviewBoard specifically approved this study. Samples from four
individual spinal cords of non-SOD1-related sporadic ALS (SALS) and three individual non-
ALS controls were used. Information on human donors is listed in Table 2. Total RNAs were
purified form the cervical region, and studies were done by RT-PCR as above. Data are
expressed as the mean + SEM with control mRNA samples as a calibrator (RQ = 1).
Fluorescent Activated Cell Scan (FACS) analysis
FACs analyses were performed as described [52]. Briefly, cells were resuspended in 0.1 mL of
binding buffer were incubated with mAb 2B7 or control mIgG for 20 min at 4°C, washed in
binding buffer to remove excess primary antibody, and immunostained with FITC-mIgG sec-
ondary antibody for 20 min at 4°C. Cells were acquired and analyzed on a FACScan-BD Sci-
ences using the Cell Quest program. As negative controls, no primary (background
fluorescence) or irrelevant mouse IgG (Sigma) were used followed by secondary antibody.
Specificity was gauged using various cells expressing different receptors.
Table 2. ALS patient and Normal Human post mortem spinal cord samples.
Sample ID Disease status Region Sex Age
VA06-60 nonSOD1 SALS Cervical M 66
VA06-11 nonSOD1 SALS Cervical F 59
VA02-58 nonSOD1 SALS Thoracic M 73
NR09-102 nonSOD1 SALS Thoracic F 39
VF07-2594 Normal Cervical M 55
VA10-17 Normal Cervical F 76
VF07-2593 Normal Cervical M 38
doi:10.1371/journal.pone.0162307.t002
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Mild reduction of samples, and biochemical analyses
2% NP-40 detergent lysates were prepared from live 293-TrkC-FL or 293-TrkC.T1 cells.
Cleared whole cell lysates were resuspended in SDS-PAGE Laemmli buffer lacking reducing
agents. After 1 min of exposure to 90°C, samples were aliquoted equally and the indicated final
molar concentration of 2-Mercaptoethanol was added to each aliquot. After 15 min at room
temperature, replicate samples were exposed again to 90°C for 1 min, others were not. All sam-
ples (0.75x106 cell equivalents/lane) were resolved immediately by SDS-PAGE. After western
transfer, membranes were immunoblotted with mAb 2B7 (TrkC-FL specific) or with mAb
C44H5 (total TrkC). Equal loading in all lanes was verified, n = 3 independent experiments.
Cell Metabolism/Survival Assays
The growth/survival profile of the cells were quantified in 96-well plates using the tetrazolium
salt reagent 4-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma) 48
hr after plating; by reading the optical density (OD), as previously described [46]. Cells cul-
tured in serum-free-medium(SFM) die by apoptosis, but they can be rescued if they express
TrkC-FL and are supplemented with NT-3. Cells received vehicle, or were supplemented with
2B7 or 2B7 fabs (tests) or mIgG (negative control) or NT-3 (positive control) at the indicated
concentrations. Cellular controls used cells expressing a related receptor TrkA, and its ligand
NGF was the positive control. TrkA-expressing cells do not respond to 2B7 (data not shown).
All assays were in quadruplicate and were repeated n>3 independent times. MTT data are
standardized to optimal dose of neurotrophin = 100% survival, and serum-freemedium (SFM)
= 0% survival, using the formula ((ODtest − ODSFM) x 100 / (ODoptimal NTF − ODSFM)).
Kinetics of activation of pro-survival signaling by 2B7 and 2B7 fabs in
vitro
293-TrkC-FL cells were cultured with 2B7 mAb (50 nM), 2B7 Fab (100 nM), NT-3 (4 nM) or
control mIgG (100 nM) for 10 min. Detergent lysates were analyzed by Western blotting with
anti-pTyr mAb 4G10 or anti-phospho-MAPK or anti-phospho-Akt (Cell Signaling). After
stripping, membrane was re-probed with anti-actin (Sigma) to standardize loading. Quantifica-
tion was done after densitometric analysis, averaging n = 3 independent experiments standard-
ized to controls (untreated or optimal NT-3 treatment).
Activation of TrkC-FL in spinal cord in vivo
A single intraperitoneal injection of 0.5 mg/kg 2B7 (~10 μg) was done in wild type C57-BL6
mice (n = 3 per group) or ALS mice (n = 5 per group), and tissue was collected ~18 hours post-
injection of 2B7 or control IgG. Detergent lysates were analyzed by Western blotting with
Anti-phospho-MAPK, anti-phospho-Akt, or anti-p-PLCγ (all from Cell Signaling). After strip-
ping, membranes were re-probed with anti-actin (Sigma) to standardize loading. Quantifica-
tion was done by densitometric analysis.
Pharmacokinetics and detection of 2B7 in the spinal cord
The pharmacokinetics of 2B7 or 2B7 Fabs were studied after intraperitoneal administration in
a 6-week old C57BL/6J (B6). The circulating levels of 2B7 or 2B7 Fabs able to bind TrkC were
quantified by ELISA based on specific binding to the known peptide epitope. Bloodwas col-
lected at different times after a single IV injection (100 μg), plasma was prepared in Heparin-
coated tubes, and assayed in ELISA. Pre-bleed was used as background control.
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For studies of 2B7 reaching motor neuron cell bodies in spinal cord, labeledmAb
(2B7-ATTO) was injected intraperitoneally into a 6-week old C57BL/6J (B6) mice in two doses
of 75 μg, 12 hr apart. After 48 hr, mice were perfused, and sections of their spinal cord were
examined by confocal microscopy.
2B7 Fabs therapeutic efficacy in SOD1 mice
B6.Cg-Tg(SOD1G93A)1Gur/J (JAX Labs, stock # 004435) mice over expressing the human
SOD1 gene with the G93Amutation, crossed into a CBL/black 6 background, an average 50%
survival at 157.1 ± 9.3 days [1]. The agonist was injected intraperitoneally three times a week at
0.5 mg/kg 2B7 Fab (~10 μg/mouse/injection), in transgenic SOD1G93Amutant mice (n = 12
mice per group, 6 males and 6 females). Treatment was initiated after disease onset was mea-
sured (e.g. when hind leg reflexes were compromised, at postnatal day ~100). Treatment was
continued until postnatal day 168. These experiments and the quantification of experimental
endpoint were done double-blinded.
Experimental endpoints in ALS
Hindlimb leg reflex (HLR) is measured as a reduction in hindlimb extension when animals are
lifted by the tail, and is an early deficit observed in mutant SOD1 Tg mice. Animals are lifted
by the base of the tail to score hindlimb extension and postural reflexes [9]. Experimental end-
points of body weight, performance in the rotarod (measurements weekly starting at day ~100,
when hind-leg reflexes were compromised), and overall survival (extension of life-span) were
done as described [53] for mutant SOD1 Tg mice ± mAb 2B7 ± control treatment. The health
of the animals was monitored daily, and there were no unexpected events.
Study Approval
All animal protocols and endpoints in these studies were specifically approved by the Univer-
sity of British Columbia and McGill University IACUC. Humane endpoints were used during
the animal survival study as described [23], and mice were euthanized when theymet the speci-
fied criteria of high loss of body weight, immobility, or Hind-leg reflex level 4 as defined in the
IACUC approved protocols. Euthanasia was done by CO2 and cervical dislocation.
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